The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics.
about
Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance PredictionPharmacodynamics of antimicrobials against Mycoplasma mycoides mycoides small colony, the causative agent of contagious bovine pleuropneumoniaIntegration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine.Comparative pharmacokinetics of cefuroxime lysine after single intravenous, intraperitoneal, and intramuscular administration to rats.Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens.Pharmacokinetic and pharmacodynamic modeling of cyadox against Clostridium perfringens in swine.Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model.Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs.Disposition kinetics of levofloxacin in sheep after intravenous and intramuscular administrationPrinciples of pharmacodynamics and their applications in veterinary pharmacology.A population pharmacokinetic approach to describe cephalexin disposition in adult and aged dogsEffect of administration route and dose escalation on plasma and intestinal concentrations of enrofloxacin and ciprofloxacin in broiler chickens.Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.Pharmacokinetics of marbofloxacin after intravenous and intramuscular administration in Hanwoo, Korean native cattleResponse of a clinical Escherichia coli strain to repeated cefquinome exposure in a piglet tissue-cage model.Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle.In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.In vivo antimicrobial activity of marbofloxacin against Pasteurella multocida in a tissue cage model in calves.Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.Veterinary drug usage and antimicrobial resistance in bacteria of animal origin.Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats.Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducksPharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers.Impact of Timing and Dosage of a Fluoroquinolone Treatment on the Microbiological, Pathological, and Clinical Outcomes of Calves Challenged with Mannheimia haemolytica.Relationship between Cefquinome PK/PD Parameters and Emergence of Resistance of Staphylococcus aureus in Rabbit Tissue-Cage Infection Model.Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration.Using In Vitro Dynamic Models To Evaluate Fluoroquinolone Activity against Emergence of Resistant Salmonella enterica Serovar Typhimurium.Pharmacokinetics of macrolides in foals.Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat.Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.Pharmacokinetics of intravenous clindamycin phosphate in captive Bennett's wallabies (Macropus rufogriseus).Limitations of MIC as sole metric of pharmacodynamic response across the range of antimicrobial susceptibilities within a single bacterial species.Plasma and synovial fluid pharmacokinetics of cefquinome following the administration of multiple doses in horses.Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Aeromonas hydrophila in Chinese soft-shelled turtles (Trionyx sinensis).Influence of flunixin on the disposition kinetic of cefepime in goats.Efficacy of a new recrystallized enrofloxacin hydrochloride-dihydrate against leptospirosis in a hamster model.Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice.Pharmacokinetic/pharmacodynamic evaluation of marbofloxacin as a single injection for Pasteurellaceae respiratory infections in cattle using population pharmacokinetics and Monte Carlo simulations.Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin in Pig against Korean Local Isolates of Actinobacillus pleuropneumoniae.Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf.
P2860
Q26753831-23A226EE-6929-428C-A54B-522CA8E1AE58Q28482671-44DCAAF4-F3DD-4373-BAA8-82B7F7015FDBQ30978577-F7450EF1-C856-438B-A520-8F7B6CBDB54BQ33571401-C77C53F6-730B-487C-8EB6-F034582AD8E5Q33720333-096321B6-F739-4F5B-A1C9-A55FD0BB71BAQ33826396-1CE538B5-26A8-4928-BFA6-28BA7907DB8DQ33843052-2759FD3D-250C-4DC4-9163-6B1B67DD822BQ33843878-A3CF2DA3-2F15-40D7-A653-85CFCCFAB0F1Q34271413-A617798A-E282-4D64-BEB7-70D6A8E35AD0Q34376757-7D4EB1A1-AA42-4E97-BFAC-871CF699311EQ34560414-BB0D989E-6AF3-457B-9ED8-97402C9FB656Q34659084-C8AACB35-8912-4F8B-9DA1-E617CE1D247BQ35127800-E68B0D1D-4260-4AE7-B737-A87A1896D3BBQ35252498-E682CBB7-CD01-4860-BE1D-D2F8B0C922DDQ35712872-B2B4386D-E99E-454A-B7E5-F948366B4C30Q35750265-4C7D55B2-F59B-4E05-8F98-E2FDBF5C87DDQ35857801-84427080-B6C4-4A5E-86EB-C70F2F8C19FBQ35884208-BBB8BAE0-E030-4A4C-A0C0-B24B95226019Q35985436-655BA123-1A48-44E4-9EE7-8249C57491D1Q36065193-707AF236-473F-466E-9889-B6012F70CAACQ36163141-4398530A-7B4B-4993-BE77-4D6EC42C28EAQ36276123-B80A0376-A424-4F87-809C-4DF196D91B28Q36437749-F6131AC6-DE48-4400-BEAF-309494B9AEC9Q36637193-BCB41671-39CD-4070-B597-96E6B23F5730Q36976649-037AE463-B802-4837-B578-D3ADB16AA496Q37247584-7A6F3059-FDA7-419E-A62C-0F58782656BEQ37613055-4C5E43F9-1259-47FF-8A6E-B9CEC16FF527Q38053461-685392D3-A1F9-45E2-92D3-AA4D53C45B77Q38081184-8F5BC783-2CDF-49B5-AD6B-444F824A3E7BQ38665480-C4903407-C178-418E-9337-D39CEFB9C79BQ38751910-482095C5-65DA-4F17-95CD-6C88C3B3C220Q39140300-C37298B4-63F4-4F95-8E05-E783B9DE5537Q39376296-808B637E-F895-4122-8376-190A8E814801Q39451183-8BAAA944-2EC6-4017-B65B-BEAE7215D1E4Q39763534-E4E5A756-E5EB-4DF3-AF9F-103600DCAB8EQ40065937-E8C056BE-8526-4F05-A1D3-A2FD0C957445Q40106417-0B003EE5-4C42-4AF4-B2BF-C9BAA418EBBEQ40199060-3BD701FB-4CCC-4FB9-84A4-71AA4EA00C54Q40220513-F1302855-E340-4EF2-91AD-339858B1DED8Q40584376-7D60FBAB-3E1E-4E66-965E-5A144D4B15C2
P2860
The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The pharmacokinetic-pharmacody ...... osage regimen for antibiotics.
@ast
The pharmacokinetic-pharmacody ...... osage regimen for antibiotics.
@en
The pharmacokinetic-pharmacody ...... osage regimen for antibiotics.
@nl
type
label
The pharmacokinetic-pharmacody ...... osage regimen for antibiotics.
@ast
The pharmacokinetic-pharmacody ...... osage regimen for antibiotics.
@en
The pharmacokinetic-pharmacody ...... osage regimen for antibiotics.
@nl
prefLabel
The pharmacokinetic-pharmacody ...... osage regimen for antibiotics.
@ast
The pharmacokinetic-pharmacody ...... osage regimen for antibiotics.
@en
The pharmacokinetic-pharmacody ...... osage regimen for antibiotics.
@nl
P2093
P1476
The pharmacokinetic-pharmacody ...... osage regimen for antibiotics.
@en
P2093
Bousquet-Mélou A
Toutain PL
del Castillo JR
P304
P356
10.1016/S0034-5288(02)00039-5
P577
2002-10-01T00:00:00Z